L&T-TECHNOLOGY-SERVICES
9.3.2023 08:31:42 CET | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, today announced a new Centre of Excellence (CoE) in Mysore (Karnataka, India) that leverages the power of the cloud with Amazon Web Services (AWS). The CoE will allow LTTS to transition its suite of cutting-edge technologies focused on the future of mobility and reduce time-to-market for end customers. By leveraging AWS infrastructure, LTTS will provide an opportunity to use AWS to support the automotive domain.
With its rich engineering domain expertise in Electric, Autonomous, and Connected Vehicles (EACV), LTTS has been helping OEMs to develop next-generation Vehicles and Aircraft that have tailored solutions focused on safety and security. The new CoE will leverage LTTS' cross-disciplinary skillsets covering embedded, mechanical, and digital facets of engineering.
LTTS has been actively working with global technology leaders like AWS to bring digital engineering solutions to end customers on the cloud. AnnotAI, Connected Cars, and SafeX are some of the LTTS solutions that will be deployed in AWS Marketplace to optimize R&D innovation on the cloud to create enterprise-leading technology solutions.
LTTS’ industry leading mobility solutions are helping OEMs to build innovative next-generation vehicles to meet and exceed the standards for transport safety, security, and emission regulations. LTTS’ AnnotAI, Connected Cars and SafeX solutions have already been deployed for leading global Automotive OEMs and Tier-1 customers, helping them reap significant faster time-to-market benefits. As part of the CoE, AWS software-defined vehicle and AWS IoT FleetWise will be used alongside LTTS’ digital offerings to collect and transfer the vehicle data to the cloud in near real time.
- AnnotAI: For the purpose of developing and testing a self-driving artificial intelligence (AI), a large amount of data is required, along with more engineering and data labeling services. LTTS’ intelligent data annotation platform AnnotAI provides smart labelling to media assets such as text, image, video, and LiDAR, thus empowering global vehicle manufacturers in their drive towards Level 5 autonomy (full driving automation or where the dynamic driving task is eliminated).
- Connected Car: LTTS’ Connected Car technologies offers automotive clients with state-of-the-art driver assistance systems, cloud services and connectivity modules which support in development of V2X platform definition, while implementing secured gateways and avoiding malicious attacks.
- SafeX: The automotive industry faces unique challenges when it comes to developing state-of-the-art software. SafeX DevOps and CI/CD automation allows automotive manufacturers to accelerate their releases while ensuring security and mitigating the risk of failed or recalled software releases.
LTTS’ suite of cutting-edge technologies has resulted in proven benefits for global customers.
A Spokesperson from BMW Group said, “The AnnotAI platform from LTTS, by enabling state-of-the-art image, video, and LiDAR data annotation capabilities on AWS, is driving a robust and integrated validation framework for BMW Group and helping the global leader in luxury vehicles engineer innovative and sustainable vehicles for the future.”
Amit Chadha, CEO and Managing Director, L&T Technology Services said, “Electric, Autonomous and Connected Vehicle (EACV) is the first of our six big bets that are helping global automotive players accelerate their technological development journey towards an autonomous and sustainable future built on the highest considerations of security and safety. By working with AWS, LTTS can help global automotive organizations realize the full potential of its high-performance and scalable technologies built on an agile AWS cloud infrastructure.”
Puneet Chandok, President of Commercial Business, AWS India & South Asia (Amazon Web Services India Pvt. Ltd.) said, “The digital transformation in the automotive industry is accelerating, in many cases thanks to innovative solutions coming from our AWS partners. LTTS’ digital engineering offerings will help our joint customers realize the benefits of moving to the cloud, such as reduced time to market, increased business value and accelerated pace of digital innovation. With the launch of the new Centre of Excellence in India, LTTS will enable customers and original equipment manufacturers (OEM) with a broader range of services and solutions to support their digital transformation journeys.”
Akshat Vaid, Partner at Everest Group said, “For some years now, innovation in mobility has been software and technology centric with themes such as hybrid and electric, autonomous driving, connected experiences, and shared mobility, continuing to be top ER&D spend segments. Cloud and edge computing are naturally at the front and centre in this new era of automotive engineering. Alliances between cloud leaders and engineering service providers will go a long way in helping OEMs in driving best engineering outcomes and in the process creating new possibilities for their end-consumers.”
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 21,600 employees spread across 22 global design centers, 28 global sales offices and 91 innovation labs as of December 31, 2022. For more information, please visit www.ltts.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005905/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom